Cardiotropic Gene Therapy for Heart Failure: Translational Lessons From AB-1002

Nghia Phu Nguyen; Phillip Tran

doi:10.1002/mef2.70046

MEDCOMM - Future Medicine ›› 2026, Vol. 5 ›› Issue (1) :e70046 DOI: 10.1002/mef2.70046

HIGHLIGHT

Cardiotropic Gene Therapy for Heart Failure: Translational Lessons From AB-1002

Nghia Phu Nguyen ¹^,²
, Phillip Tran ¹^,³

Author information +

History +

PDF

Cite this article

Download citation ▾

Nghia Phu Nguyen, Phillip Tran. Cardiotropic Gene Therapy for Heart Failure: Translational Lessons From AB-1002. MEDCOMM - Future Medicine, 2026, 5(1): e70046 DOI:10.1002/mef2.70046

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	T. D. Henry, E. S. Chung, M. Alvisi, et al., “Cardiotropic AAV Gene Therapy for Heart Failure: A Phase 1 Trial,” Nature Medicine31 (2025): 3845–3852.

[2]	H. Zhang, Q. Zhan, B. Huang, Y. Wang, and X. Wang, “AAV-Mediated Gene Therapy: Advancing Cardiovascular Disease Treatment,” Frontiers in Cardiovascular Medicine9 (2022): 952755.

[3]	K. Ishikawa, K. M. Fish, L. Tilemann, et al., “Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure,” Molecular Therapy22 (2014): 2038–2045.

[4]	S. Van Linthout, K. Stellos, M. Giacca, et al., “State of the Art and Perspectives of Gene Therapy in Heart Failure,” European Journal of Heart Failure27 (2025): 5–25.

[5]	A. Pathak, F. del Monte, W. Zhao, et al., “Enhancement of Cardiac Function and Suppression of Heart Failure Progression by Inhibition of Protein Phosphatase 1,” Circulation Research96 (2005): 756–766.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).